Predictive Oncology insider receives 64,680 RSUs; vesting Oct 31, 2025

Rhea-AI Filing Summary

Predictive Oncology Inc. (POAI) director Veena Rao was granted 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock on vesting, and the grant was recorded at a $0.00 acquisition price. Following the award, Ms. Rao's reported beneficial ownership increased to 73,797 shares. The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through the vesting date. The filing identifies the transaction as an acquisition by the reporting person in their capacity as a director and shows the report was submitted by one reporting person.

Positive

• Alignment with shareholders: Director granted equity that vests with service, aligning interests with long-term shareholder value
• Retention incentive: Full vesting date provides a clear retention schedule through October 31, 2025

Negative

• Potential dilution: RSUs will convert to common shares on vesting, increasing outstanding share count (dilution magnitude not provided)
• No valuation disclosed: Filing lists price as $0.00 and does not provide grant fair value or impact on outstanding shares

Insights

Corporate Governance Expert

TL;DR: A routine director equity grant aligns executive incentives with shareholders without immediate dilution.

The award of 64,680 RSUs to a director is a standard long-term incentive to align interests with shareholders and retain board members. The RSUs carry a service-based vesting provision, vesting in full on October 31, 2025, which ties compensation to continued engagement rather than immediate liquidity. Because the RSUs convert to common shares on vesting and were granted at a $0.00 price, they will increase share count upon settlement, but the filing does not quantify potential dilution relative to outstanding shares, so materiality cannot be assessed from this form alone.

Securities Analyst

TL;DR: Insider received a sizeable equity grant that raises reported beneficial ownership; impact appears routine and non-eventful.

The Form 4 reports an acquisition-coded grant of RSUs representing 64,680 shares, increasing the reporting person’s beneficial ownership to 73,797 shares. The grant price is listed as $0.00, consistent with compensation-based awards. The vesting date is fixed and service-contingent. The filing does not disclose grant accounting values, total outstanding shares, or dilution percentage, so investor-level valuation impact cannot be determined from this disclosure alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rao Veena

(Last) (First) (Middle)

C/O PREDICTIVE ONCOLOGY INC.

91 43RD STREET, SUITE 110

(Street)

PITTSBURGH PA 15201

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Predictive Oncology Inc. [ POAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A		64,680(1)	A	$0.00	73,797	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs shall vest in full on October 31, 2025, subject to continued service through the applicable vesting date.

	/s/ Josh Blacher, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Predictive Oncology (POAI) report in this Form 4?

The filing reports that director Veena Rao was granted 64,680 RSUs, increasing her reported beneficial ownership to 73,797 shares.

When do the RSUs granted to Veena Rao vest?

The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through that date.

What price was recorded for the RSU grant on the Form 4?

The transaction is recorded with a $0.00 acquisition price, consistent with compensation awards.

Does the Form 4 indicate whether the grant is part of a 10b5-1 plan or similar?

The Form 4 does not indicate that the transaction was made pursuant to a 10b5-1 plan; it is reported as an acquisition grant.

How much of Veena Rao’s ownership is from this grant versus prior holdings?

The Form 4 shows 64,680 RSUs were acquired and total beneficial ownership of 73,797 shares after the transaction; the filing does not break out prior holdings separately.